Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iodine→

Iodine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7553-56-2
Molecular formula
I2
Molecular weight
253.8089 g/mol
Drug class
Halogen antiseptic and essential trace elementthyroid-hormone substrate
Mechanism of action
As an antiseptic, free iodine reacts with and oxidises microbial proteins, nucleotides and membrane components, producing broad antimicrobial activity. Physiologically, iodide is taken up by the thyroid and incorporated into thyroxine (T4) and triiodothyronine (T3).
Indications / reported uses
  • Topical antiseptic use in iodine solutions and iodophor preparations, according to formulation and route.
  • Prevention and treatment of iodine deficiency with appropriately formulated dietary or medicinal products.

Sources: https://www.cdc.gov/infection-control/hcp/disinfection-sterilization/chemical-disinfectants.html · https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Iodine Environmental Risk Assessment (ERA) (the Iodine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.